Year: 2026

NEW YORK, NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) — Peace Acquisition Corp (the “Company”) announced today that it priced its initial public offering of 6,000,000 units at $10.00 per unit. The Company’s units will be listed on the Nasdaq Capital Market (“Nasdaq”) and will begin trading on May 22, 2026, under the ticker symbol “PECEU.” Each unit consists of one ordinary share, one right entitling its holder to receive one fifth of one ordinary share upon the Company’s completion of an initial business combination and one warrant entitling its holder to purchase one Ordinary Share for $11.50 per share, subject to adjustment. Once the securities comprising the units begin separate trading, the ordinary shares, rights and warrants are expected to be listed on Nasdaq under the symbols “PECE,” “PECER” and “PECEW,” respectively. The Company...

Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026. Poster Presentation Title: Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune Checkpoint InhibitorsPresenter: Timothy A. Yap, MBBS, Ph.D., University of Texas, M.D. Anderson Cancer CenterSession: Developmental Therapeutics – ImmunotherapyDate: Saturday, May 30, 2026, 1:30 – 4:30...

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026 [²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026 Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were consistent with previously disclosed findings at AACR as of March 4, 2026 with continued deepening of responses; additional updates expected in late 2026 All three clinical programs continue to be well-tolerated based on safety findings reported...

LONDON, May 21, 2026 (GLOBE NEWSWIRE) — nVent (NYSE: NVT), a global leader in electrical connection and protection solutions, today announced its participation in William Blairs 46th Annual Growth Stock Conference on Wednesday, June 3, 2026. Beth Wozniak, Chair and Chief Executive Officer, will present at 8:00 a.m. CST. A webcast will be available on nVent’s Investor Relations website at https://investors.nvent.com/events-and-presentations. About nVentnVent is a leading global provider of electrical connection and protection solutions. We believe our inventive electrical solutions enable safer systems and ensure a more secure world. We design, manufacture, market, install and service high performance products and solutions that connect and protect some of the world’s most sensitive equipment, buildings and critical processes....

In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse events Activity of the combined regimen across all dose cohorts achieved 39% ORR and 7.3-month median PFS In the 250 mg QD 5:2 intermittent dose cohort, 50% ORR, 9.2-month median DOR, and low frequency of high-grade adverse events was observed, suggesting a potential optimal dose combinationSAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that data from Part 1 of the Phase 1b MUIR trial will be presented at the 2026 American Society...

KUALA LUMPUR, Malaysia, May 21, 2026 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (“VCI Global” or the “Company”) today announced that it received a notification letter from the Nasdaq Stock Market LLC (“NASDAQ”) on May 19, 2026 regarding the delayed filing of the Company’s Form 20-F for the financial year ended December 31, 2025. The notice relates to the timing of the Company’s filing of its Form 20-F under NASDAQ Listing Rule 5250(c)(1), which requires listed companies to periodically file financial reports with the U.S. Securities and Exchange Commission (“SEC”). As previously disclosed, the Company filed a Form 12b-25 (Notification of Late Filing) with the SEC on May 1, 2026, after requiring additional time to complete the preparation and final review of its financial statements and related disclosures for the 2025...

Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Combined results evaluating AKY-2519 across several B7-H3 expressing tumor types, including metastatic castration-resistant prostate cancer (mCRPC), suggest a potentially differentiated profile compared to approved radiopharmaceuticals Aktis to hold conference call on Wednesday, May 27, 2026, at 8:00 a.m. ET with leading clinical investigators, Oliver Sartor, M.D., and Timothy Yap, MBBS, Ph.D., to discuss resultsBOSTON, May 21, 2026 (GLOBE NEWSWIRE) — Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today...

Cash Runway Extended to Finance the Parkinson’s Program; Debt Paydown Improves Shareholder Equity Position  Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) — Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced the closing of its registered direct offering, pursuant to the securities purchase agreements with certain investors, for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering were approximately $2.0 million (the “Offering”). “Yesterday’s capital raise helps the Company prepare for key milestones anticipated in the next year,” said Christer Rosén, Chairman and CEO of Jupiter...

Preliminary mPFS of 15.2 months; mDOR not reached Robust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastases ORR 60% in patients with a broad spectrum of EGFR-NCMs, including PACC Dose dependent and manageable AE profile, no new safety signals observed Webcast on Thursday, May 21, 2026 at 5:30 pm EDTCAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced positive results from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) non-classical mutations (NCMs). These data will be presented by Julia Rotow, M.D., Clinical Director,...